Nammi Therapeutics utilizes nanocarriers to deliver synergistic anti-tumor and immunomodulatory combinations to the tumor microenvironment. An immunogenic cell death inducing chemotherapy primes the cancer site for recruitment of cytotoxic T cells in solid tumors. The response is sustained and synergistically enhanced by co-delivery of an immune adjuvant. The combined effect represents a unique mechanism of action providing a robust, systemic anti-tumor immune response, which can eliminate primary and metastatic disease, with immune memory. To date Nammi has raised ~$8M and is in late preclinical development with its first product with an IND scheduled for December 2019. Nammi has an exclusive license to the IP portfolio protecting the concept and specific products. A seasoned drug development management team is working with the scientific founders to continue to innovate novel products while prioritizing the efficient development of the initial product.